Celcuity INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ

26 Mar 2026

CELC

10-K: Celcuity's Gedatolisib NDA Accepted with Priority Review

Celcuity Inc. announced the FDA's acceptance of its New Drug Application for gedatolisib with Priority Review, targeting HR+/HER2advanced breast cancer, following strong Phase 3 clinical trial results.

NASDAQ

31 Mar 2025

CELC

Celcuity INC

10-K: Celcuity Inc. Details Capital Stock, Warrants, and Anti-Takeover Measures in 10-K Filing

Celcuity Inc.'s 10-K filing provides a detailed overview of its capital stock structure, outstanding warrants, and measures in place to deter potential takeovers as of December 31, 2024.

NASDAQ

27 Mar 2024

CELC

Celcuity INC

10-K: Celcuity Inc. Details Capital Structure and Regulatory Compliance in 10-K Filing

Celcuity Inc.'s 10-K filing outlines its capital structure, including common and preferred stock, warrants, and compliance with securities regulations.